About The Study:

Non-erosive reflux disease (NERD) is a type of gastroesophageal reflux disease when the esophagus is not harmed by the stomach acid. If treated it can remain under control but if left untreated the disease can worsen, leading to very poor digestive health. Heartburn is the main symptom felt but others include chest pain, the feeling of a lump in your throat, a hard time swallowing, burping up, or regurgitating your food. NERD can also lead to a persistent cough, laryngitis, problems sleeping, and asthma. There are risk factors when experiencing NERD at a young age, and doctors believe that children could have inherited this disease from their parents. Some treatment options include taking antacids, getting a proton-pump inhibitor, and antidiarrheal meds. The study that Rochester Clinical Research is conducting is testing a tegoprazan oral pill that is taken daily for either 4 weeks or 20 weeks. Tegaprazan is a potassium competitive acid blocker that is used to treat GERD which is similar to NERD. The study is for people 18 years old and older and is about 28 weeks long. It is a phase 3 form of treatment that is getting close to getting FDA approved.

Study-related care is available to participants at no cost and health insurance is not required nor needed. Compensation is also available for your time and travel to participate.


  • 18+ years old
  • Have experienced heartburn (burning sensation, pain at posterior bony thorax) for at least 6 months
  • Have documented history of symptomatic GERD
  • Have no mucosal breaks on the upper GI endoscopy
  • *Please note, that other conditions may apply